Ocugen
-
Malvern Gene Company to Raise $115M from Convertible Notes While Dealing with Stock Decline
Malvern-based Ocugen saw its stock fall almost 20 percent after an announcement to use convertible notes to pay down existing debt and fund ongoing drug…
-
Done Deal: Malvern Company to Co-Develop COVID-19 Vaccine for U.S. Market
Malvern-based Ocugen has finalized a deal with Bharat Biotech to develop the India-based company’s COVID-19 vaccine, Covaxin, for the U.S. market, writes John George for…
Founding Partners
Advertisement
Affiliate Partners
Chamber Partners
